{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T03:27:56Z","timestamp":1771039676084,"version":"3.50.1"},"reference-count":8,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.bulcan.2024.10.007","type":"journal-article","created":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T16:17:31Z","timestamp":1731773851000},"page":"6-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tislelizumab en monoth\u00e9rapie ou associ\u00e9 \u00e0 une chimioth\u00e9rapie dans le cancer bronchique non \u00e0 petites cellules localement avanc\u00e9 ou m\u00e9tastatique"],"prefix":"10.1016","volume":"112","author":[{"given":"Alexandre","family":"Olivier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9mence","family":"Basse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bulcan.2024.10.007_bib0045","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41571-018-0138-4","article-title":"A banner year for immunotherapy and targeted therapy","volume":"16","author":"Carlisle","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2024.10.007_bib0050","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.bulcan.2018.07.016","article-title":"Data from the AACR 2018\u00a0meeting on the combination chimio-immunotherapy on advanced non-small cells lung cancer (NSCLC)","volume":"105","author":"Simonneau","year":"2018","journal-title":"Bull Cancer (Paris)"},{"issue":"7\u20138","key":"10.1016\/j.bulcan.2024.10.007_bib0055","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.bulcan.2020.04.018","article-title":"Immunotherapy of metastatic non-small cell lung cancer from first line to resistance and its management","volume":"107","author":"Basse","year":"2020","journal-title":"Bull Cancer (Paris)"},{"issue":"10","key":"10.1016\/j.bulcan.2024.10.007_bib0060","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","article-title":"Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy","volume":"18","author":"Shepherd","year":"2000","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bulcan.2024.10.007_bib0065","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","article-title":"The binding of an anti-PD-1\u00a0antibody to Fc\u03b3RI has a profound impact on its biological functions","volume":"67","author":"Zhang","year":"2018","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"10.1016\/j.bulcan.2024.10.007_bib0070","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","article-title":"Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3\u00a0randomized clinical trial","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2024.10.007_bib0075","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jtho.2021.05.005","article-title":"Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): a randomized phase 3\u00a0trial","volume":"16","author":"Lu","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2024.10.007_bib0040","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jtho.2022.09.217","article-title":"Tislelizumab versus docetaxel in patients with previously treated advanced NSCLC (RATIONALE-303): a phase 3, open-label, randomized controlled trial","volume":"18","author":"Zhou","year":"2023","journal-title":"J Thorac Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124003941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124003941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T20:39:45Z","timestamp":1736368785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455124003941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0007455124003941"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.10.007","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tislelizumab en monoth\u00e9rapie ou associ\u00e9 \u00e0 une chimioth\u00e9rapie dans le cancer bronchique non \u00e0 petites cellules localement avanc\u00e9 ou m\u00e9tastatique","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}